
Stoke Therapeutics, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Stoke Therapeutics is a biopharmaceutical company developing antisense oligonucleotide medicines that restore protein levels by targeting RNA, with lead programs focused on genetic epilepsies such as Dravet syndrome and other diseases caused by haploinsufficiency.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Kaye Edward M. MDInsider | Sell | $382K | 11,930at $32.01 | Aug 18, 2026 |
| Ticho BarryCHIEF MEDICAL OFFICER | Sell | $145K | 4,525at $32.01 | Aug 18, 2026 |
| Allan JonathanGENERAL COUNSEL & CORP SEC | Sell | $87K | 2,716at $32.01 | Aug 18, 2026 |
| Kaye Edward M. MDInsider | Sell | $21K | 637at $32.47 | Aug 18, 2026 |
| Ticho BarryCHIEF MEDICAL OFFICER | Sell | $8K | 242at $32.47 | Aug 18, 2026 |
| Allan JonathanGENERAL COUNSEL & CORP SEC | Sell | $5K | 145at $32.47 | Aug 18, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable STOK activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.